Human Genome Epidemiology Literature Finder
Records 1 - 9 (of 9 Records) |
Query Trace: Vomiting and TP53[original query] |
---|
Nucleotide excision repair gene polymorphisms may predict acute toxicity in patients treated with chemoradiotherapy for bladder cancer. Pharmacogenomics 2010 Oct 11 (10): 1377-87. Sakano Shigeru, Hinoda Yuji, Sasaki Miwa, Wada Takashi, Matsumoto Hiroaki, Eguchi Satoshi, Shinohara Asano, Kawai Yoshihisa, Hara Tomohiko, Nagao Kazuhiro, Hara Takahiko, Naito Katsusuke, Matsuyama Hideya |
Phase I study of pazopanib and vorinostat: a therapeutic approach for inhibiting mutant p53-mediated angiogenesis and facilitating mutant p53 degradation. Annals of oncology : official journal of the European Society for Medical Oncology / ESMO 2015 May 26 (5): 1012-8. Fu S, Hou M M, Naing A, Janku F, Hess K, Zinner R, Subbiah V, Hong D, Wheler J, Piha-Paul S, Tsimberidou A, Karp D, Araujo D, Kee B, Hwu P, Wolff R, Kurzrock R, Meric-Bernstam |
Phosphatidylinositol 3-Kinase ?-Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study. Journal of clinical oncology : official journal of the American Society of Clinical Oncology 2018 2 36 (13): 1291-1299. Juric Dejan, Rodon Jordi, Tabernero Josep, Janku Filip, Burris Howard A, Schellens Jan H M, Middleton Mark R, Berlin Jordan, Schuler Martin, Gil-Martin Marta, Rugo Hope S, Seggewiss-Bernhardt Ruth, Huang Alan, Bootle Douglas, Demanse David, Blumenstein Lars, Coughlin Christina, Quadt Cornelia, Baselga Jo |
A phase I study of the HDM2 antagonist SAR405838 combined with the MEK inhibitor pimasertib in patients with advanced solid tumours. British journal of cancer 2018 12 120 (3): 286-293. de Weger Vincent A, de Jonge Maja, Langenberg Marlies H G, Schellens Jan H M, Lolkema Martijn, Varga Andrea, Demers Brigitte, Thomas Koruth, Hsu Karl, Tuffal Gilles, Goodstal Samantha, Macé Sandrine, Deutsch Er |
Phase I study of tirabrutinib (ONO-4059/GS-4059) in patients with relapsed or refractory B-cell malignancies in Japan. Cancer science 2019 3 110 (5): 1686-1694. Munakata Wataru, Ando Kiyoshi, Hatake Kiyohiko, Fukuhara Noriko, Kinoshita Tomohiro, Fukuhara Suguru, Shirasugi Yukari, Yokoyama Masahiro, Ichikawa Satoshi, Ohmachi Ken, Gion Naokazu, Aoi Arata, Tobinai Kens |
[Cerebrospinal fluid TP53 gene mutation in patients with lung cancer associated meningitis and its clinical implications]. Zhonghua yi xue za zhi 2020 4 100 (11): 823-827. Li X Q, Huang M, Chen X X, Zou Y L, Yan L T, Zhao H, He J Y, Bu |
Phase 1 study of the MDM2 antagonist RO6839921 in patients with acute myeloid leukemia. Investigational new drugs 2020 2 38 (5): 1430-1441. Uy Geoffrey L, Assouline Sarit, Young Anne-Marie, Blotner Steven, Higgins Brian, Chen Lin-Chi, Yee Kar |
Phase I studies of vorinostat with ixazomib or pazopanib imply a role of antiangiogenesis-based therapy for TP53 mutant malignancies. Scientific reports 2020 2 10 (1): 3080. Wang Yudong, Janku Filip, Piha-Paul Sarina, Hess Kenneth, Broaddus Russell, Liu Lidong, Shi Naiyi, Overman Michael, Kopetz Scott, Subbiah Vivek, Naing Aung, Hong David, Tsimberidou Apostolia M, Karp Daniel, Yao James, Fu Siqi |
First-in-human phase I study of TQ-B3139 (CT-711) in advanced non-small cell lung cancer patients with ALK and ROS1 rearrangements. European journal of cancer (Oxford, England : 1990) 2022 Sep 173 238-249. Ma Yuxiang, Zhao Hongyun, Xue Jinhui, Liu Li, Yang Nong, Zhang Yang, Yang Haiyan, Hong Shaodong, Xiong Yi, Zhang Zhonghan, Zeng Liang, Pan Hui, Zhou Chunhua, Zhang Yongchang, Wang Xunqiang, Han Xi, Wan Xiaojing, Shao Yang, Liu Jingwen, Yang Yunpeng, Huang Yan, Zhao Yuanyuan, Fang Wenfeng, Li Su, Zhang |
- Page last reviewed:Feb 1, 2024
- Content source: